Registration Number
0217U006007,
0114U001166
, R & D reports
Title
To study metabolic and genetic mechanisms of thrombotic disorders in patients with ischemic heart disease combined with diabetes mellitus
popup.stage_title
Head
S. Serik,
Registration Date
25-01-2017
Organization
Government Institution "L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine"
popup.description2
The study enrolled 297 patients with CHD and CHD combined with type 2 diabetes which were subsequently followed up and 30 persons as a control group. Methods: anthropometric measurements, evaluation of serum carbohydrate metabolism and lipid spectrum, platelets' quantity and quality, determination of residual platelet reactivity (НRPR) by induced (ADP, arachidonic acid) platelet aggregation, immunoinflammatory activity, oxidative stress and genetic research. It was found that in the group of the followed up residents of Kharkiv region frequencies of genotypes and alleles of polymorphic sites C807T (rs1126643) and T924C (rs4523) of the platelet receptors' genes ITGA2 and TBXA2R are compatible with Hardy-Weinberg equilibrium and are close to these frequencies in Western European populations. In CHD patients heterozygous genotype of the polymorphic site T924C (rs4523) of the TBXA2R gene was significantly associated with DM. It is proved that in patients with CHD presence of the mutant allele T in the polymorphic site C807T (rs1126643) of the ITGA2 gene increases the risk of high RPR to the acetylsalicylic acid (ASA) (2=4,81). This effect was not confirmed by the analysis of CHD patients without type 2 DM, but gained a high significance in patients with CHD combined with type 2 DM (2=6,79). Patients with TT genotype in the polymorphism T924C (rs4523) of the TBXA2R gene were found to have a significantly worse disease progression with more cardiovascular events compared with the wild homozygotes and heterozygotes. We developed a new method of the secondary prevention of atherothrombosis in patients with CHD and type 2 DM, according to which the dosing of the ASA in therapeutically effective and safe dose is determined considering the average platelet volume (MPV) and platelet distribution width by volume (PDW).
Product Description
popup.authors
Бондар Т.М.
Бугріменко Г.П.
Волков В.І.
Воронова Н.І.
Горб Ю.Г.
Запровальная О.Є.
Зоренко Н.В.
Кірюхіна О.В.
Комір І.Р.
Мороз О.С.
Оврах Т.Г.
Оклей О.В.
Рябуха В.В.
Самохіна Л.М.
Сердобинська-Канівець Е.М.
Строна В.І.
Ткаченко О.В.
Ченчик Т.М.
Щенявська О.М.
popup.nrat_date
2020-04-02
